Pipamperone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pipamperone
Accession Number
DB09286
Type
Small Molecule
Groups
Approved, Investigational
Description

Pipamperone is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia. It was discovered at Janssen Pharmaceutica in 1961, and entered clinical trials in the United States in 1963.

Structure
Thumb
Synonyms
  • Carpiperone
  • Floropipamide
  • Fluoropipamide
Product Ingredients
IngredientUNIICASInChI Key
Pipamperone hydrochlorideIT085U64JB2448-68-2BMXXSXQVMCXGJM-UHFFFAOYSA-N
International/Other Brands
Dipiperal / Dipiperon / Piperonil / Piperonyl / Propitan
Categories
UNII
5402501F0W
CAS number
1893-33-0
Weight
Average: 375.488
Monoisotopic: 375.232205381
Chemical Formula
C21H30FN3O2
InChI Key
AXKPFOAXAHJUAG-UHFFFAOYSA-N
InChI
InChI=1S/C21H30FN3O2/c22-18-8-6-17(7-9-18)19(26)5-4-12-24-15-10-21(11-16-24,20(23)27)25-13-2-1-3-14-25/h6-9H,1-5,10-16H2,(H2,23,27)
IUPAC Name
1'-[4-(4-fluorophenyl)-4-oxobutyl]-[1,4'-bipiperidine]-4'-carboxamide
SMILES
NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1

Pharmacology

Indication

Used in the treatment of schizophrenia.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePipamperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePipamperone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePipamperone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pipamperone.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Pipamperone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pipamperone.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Pipamperone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pipamperone.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Pipamperone.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Pipamperone is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Pipamperone.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Pipamperone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pipamperone.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Pipamperone.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Pipamperone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pipamperone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Pipamperone.Experimental
AmphetaminePipamperone may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pipamperone.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Pipamperone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Pipamperone.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pipamperone.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pipamperone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Pipamperone.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pipamperone.Approved
AtenololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Azaperone.Investigational, Vet Approved
AzelastinePipamperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Azilsartan medoxomil.Approved
BaclofenThe risk or severity of adverse effects can be increased when Pipamperone is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Pipamperone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Pipamperone.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Pipamperone.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Pipamperone.Approved
BenzphetaminePipamperone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pipamperone.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Pipamperone.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Betaxolol.Approved
BisoprololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Pipamperone.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pipamperone is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pipamperone.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipamperone.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Pipamperone.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pipamperone.Approved, Investigational
BuprenorphinePipamperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pipamperone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pipamperone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Pipamperone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Pipamperone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Pipamperone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pipamperone.Approved, Illicit, Vet Approved
CabergolineThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Cabergoline.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Pipamperone.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pipamperone.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Pipamperone.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Pipamperone.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Carisoprodol.Approved
CarteololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Carvedilol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pipamperone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pipamperone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Pipamperone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pipamperone.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Chlorphenamine.Approved
ChlorphenterminePipamperone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pipamperone.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pipamperone.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Chlorzoxazone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Pipamperone.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pipamperone.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Pipamperone.Approved
ClemastineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Pipamperone.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Pipamperone.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pipamperone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Pipamperone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Pipamperone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pipamperone.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Pipamperone.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipamperone.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pipamperone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Pipamperone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pipamperone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pipamperone.Approved
DetomidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pipamperone.Approved, Vet Approved
DextroamphetaminePipamperone may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pipamperone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pipamperone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pipamperone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Pipamperone.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Pipamperone.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Diclofenamide.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Pipamperone is combined with Diethyl ether.Experimental
DiethylpropionPipamperone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pipamperone.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pipamperone.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pipamperone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pipamperone.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Pipamperone is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pipamperone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pipamperone.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Pipamperone.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Pipamperone.Experimental, Illicit
DuloxetinePipamperone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pipamperone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Pipamperone.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Pipamperone is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Pipamperone.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pipamperone.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pipamperone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pipamperone.Approved, Investigational, Vet Approved
EntacaponeThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Pipamperone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipamperone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pipamperone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Pipamperone.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pipamperone.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Pipamperone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pipamperone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Pipamperone is combined with Etacrynic acid.Approved
EthanolPipamperone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipamperone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pipamperone.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pipamperone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pipamperone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Pipamperone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Pipamperone.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Pipamperone.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipamperone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pipamperone.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pipamperone.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Pipamperone.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pipamperone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pipamperone.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pipamperone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pipamperone.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Pipamperone.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pipamperone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pipamperone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pipamperone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pipamperone.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Pipamperone.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pipamperone.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Pipamperone.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pipamperone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Pipamperone.Approved, Illicit, Investigational
GepefrinePipamperone may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Pipamperone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Pipamperone.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Pipamperone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pipamperone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Pipamperone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Pipamperone.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pipamperone.Approved
HydralazineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Pipamperone.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipamperone.Approved, Illicit
HydroxyamphetaminePipamperone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Pipamperone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Pipamperone.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Indapamide.Approved
IndiplonThe risk or severity of adverse effects can be increased when Pipamperone is combined with Indiplon.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Pipamperone.Withdrawn
Iofetamine I-123Pipamperone may decrease the stimulatory activities of Iofetamine I-123.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pipamperone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pipamperone.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Isradipine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pipamperone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pipamperone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pipamperone.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Pipamperone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Pipamperone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Pipamperone.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Levocetirizine.Approved
LevodopaPipamperone may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pipamperone.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Pipamperone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pipamperone.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Pipamperone.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Pipamperone.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Pipamperone.Approved, Investigational
LisdexamfetaminePipamperone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Pipamperone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Pipamperone.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Pipamperone.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pipamperone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Pipamperone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Lormetazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pipamperone.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pipamperone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Pipamperone is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Pipamperone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Pipamperone.Approved, Investigational
MephedronePipamperone may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePipamperone may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pipamperone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pipamperone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Meptazinol.Experimental
MequitazinePipamperone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pipamperone.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Pipamperone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Pipamperone.Approved, Illicit
MethamphetaminePipamperone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pipamperone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pipamperone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pipamperone.Approved
MethotrimeprazinePipamperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pipamperone.Approved, Investigational, Vet Approved
MethoxyphenaminePipamperone may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pipamperone.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pipamperone.Approved
MetipranololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pipamperone.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metoprolol.Approved, Investigational
MetyrosinePipamperone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Pipamperone.Approved, Illicit
MidomafetaminePipamperone may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Pipamperone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Minoxidil.Approved
MirtazapinePipamperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAPipamperone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pipamperone.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Pipamperone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pipamperone.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Pipamperone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pipamperone.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Pipamperone.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Pipamperone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Pipamperone.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Pipamperone.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pipamperone.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Pipamperone.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Pipamperone.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pipamperone.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Pipamperone.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pipamperone.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pipamperone.Approved
OpiumThe risk or severity of adverse effects can be increased when Pipamperone is combined with Opium.Approved, Illicit
OrphenadrinePipamperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Pipamperone.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pipamperone.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pipamperone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pipamperone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pipamperone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pipamperone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pipamperone.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pipamperone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Papaverine.Approved
ParaldehydePipamperone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Pipamperone.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pipamperone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pipamperone.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
PerazineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Pipamperone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pipamperone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pipamperone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pipamperone.Approved
PhenibutThe risk or severity of adverse effects can be increased when Pipamperone is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pipamperone.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Pipamperone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Phenoxyethanol.Approved
PhenterminePipamperone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Pipamperone.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Pipamperone.Approved
PindololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pindolol.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pomalidomide.Approved
PramipexolePipamperone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Pipamperone.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pipamperone.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Pipamperone.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Pipamperone.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Pipamperone.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipamperone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Pipamperone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Pipamperone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pipamperone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Pipamperone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Pipamperone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Pipamperone.Investigational
PseudoephedrinePipamperone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Pipamperone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipamperone.Approved
QuinagolideThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Quinagolide.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Quinapril.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pipamperone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pipamperone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pipamperone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pipamperone.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Pipamperone is combined with Riociguat.Approved
RisperidonePipamperone may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ritanserin.Investigational
RitobegronPipamperone may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Pipamperone.Approved
RomifidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Romifidine.Vet Approved
RopinirolePipamperone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pipamperone.Approved
RotigotinePipamperone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pipamperone.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sacubitril.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pipamperone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Pipamperone.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Pipamperone.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Pipamperone.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pipamperone.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
SotalolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Pipamperone is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pipamperone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Pipamperone.Approved, Investigational
SuvorexantPipamperone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Pipamperone.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pipamperone.Approved
TerazosinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Terazosin.Approved
Testosterone PropionateThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Testosterone Propionate.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pipamperone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pipamperone.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pipamperone.Investigational
ThalidomidePipamperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pipamperone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pipamperone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pipamperone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pipamperone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tilidine.Experimental
TimololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pipamperone.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pipamperone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pipamperone.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Pipamperone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pipamperone.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipamperone.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pipamperone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pipamperone.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Valsartan.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pipamperone.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Pipamperone.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Pipamperone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Pipamperone is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pipamperone.Approved
XenonThe risk or severity of adverse effects can be increased when Pipamperone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pipamperone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pipamperone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pipamperone.Approved, Investigational
ZolpidemPipamperone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Pipamperone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Pipamperone.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipamperone.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D02622
PubChem Compound
4830
PubChem Substance
310265179
ChemSpider
4664
BindingDB
81483
ChEBI
78549
ChEMBL
CHEMBL440294
Wikipedia
Pipamperone
ATC Codes
N05AD05 — Pipamperone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentChronic Schizophrenia / Schizoaffective Disorders1
2CompletedTreatmentDepression1
3CompletedTreatmentMajor Depressive Disorder (MDD)1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.182 mg/mLALOGPS
logP2.32ALOGPS
logP1.87ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)15.94ChemAxon
pKa (Strongest Basic)8.69ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area66.64 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity105.1 m3·mol-1ChemAxon
Polarizability41.16 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Phenylbutylamines / Butyrophenones / Piperidinecarboxamides / Aryl alkyl ketones / Benzoyl derivatives / Aminopiperidines / Fluorobenzenes / Aryl fluorides / Gamma-amino ketones / Trialkylamines
show 6 more
Substituents
Alkyl-phenylketone / Butyrophenone / Phenylbutylamine / Piperidinecarboxamide / Benzoyl / Aryl alkyl ketone / Fluorobenzene / 4-aminopiperidine / Halobenzene / Aryl fluoride
show 20 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, tertiary amino compound, monocarboxylic acid amide, aromatic ketone, bipiperidines (CHEBI:78549)

Drug created on October 29, 2015 12:11 / Updated on December 01, 2017 17:22